166 related articles for article (PubMed ID: 22080965)
1. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
Singh SN; Cao Q; Gojo I; Rapoport AP; Akpek G
Bone Marrow Transplant; 2012 Jul; 47(7):1008-9. PubMed ID: 22080965
[No Abstract] [Full Text] [Related]
2. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
[No Abstract] [Full Text] [Related]
3. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
[TBL] [Abstract][Full Text] [Related]
4. Decitabine treatment for acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.
Liu XL; Zhao X; Wang C; Gao SJ; Tan YH
J Biol Regul Homeost Agents; 2017; 31(1):171-175. PubMed ID: 28337888
[TBL] [Abstract][Full Text] [Related]
5. Studies of decitabine with allogeneic progenitor cell transplantation.
Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
[TBL] [Abstract][Full Text] [Related]
6. Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation.
Ustun C; Kalla A; Farrow S; DeRemer DL; Jillella A
Am J Hematol; 2008 Oct; 83(10):825-7. PubMed ID: 18767131
[No Abstract] [Full Text] [Related]
7. Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
Cashen AF; Devine H; DiPersio J
Am J Hematol; 2006 Jul; 81(7):543-5. PubMed ID: 16755561
[TBL] [Abstract][Full Text] [Related]
8. A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy.
Kara A; Akın Belli A; Karakuş V; Dere Y; Kurtoğlu E
Turk J Haematol; 2017 Jun; 34(2):192-193. PubMed ID: 28183685
[No Abstract] [Full Text] [Related]
9. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
[TBL] [Abstract][Full Text] [Related]
10. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ
Leuk Lymphoma; 2013 Sep; 54(9):2003-7. PubMed ID: 23270581
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F
Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218
[No Abstract] [Full Text] [Related]
12. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
[TBL] [Abstract][Full Text] [Related]
13. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
Lübbert M; Bertz H; Rüter B; Marks R; Claus R; Wäsch R; Finke J
Bone Marrow Transplant; 2009 Nov; 44(9):585-8. PubMed ID: 19363531
[TBL] [Abstract][Full Text] [Related]
14. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
[TBL] [Abstract][Full Text] [Related]
15. Decitabine studies in chronic and acute myelogenous leukemia.
Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
[No Abstract] [Full Text] [Related]
16. Hypomethylating agents and chemotherapy in MDS.
Adès L; Santini V
Best Pract Res Clin Haematol; 2013 Dec; 26(4):411-9. PubMed ID: 24507817
[TBL] [Abstract][Full Text] [Related]
17. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.
Phillips CL; Davies SM; McMasters R; Absalon M; O'Brien M; Mo J; Broun R; Moscow JA; Smolarek T; Garzon R; Blum W; Schwind S; Marcucci G; Perentesis JP
Br J Haematol; 2013 May; 161(3):406-10. PubMed ID: 23432727
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
[No Abstract] [Full Text] [Related]
19. Effect of Decitabine Combined with Unrelated Cord Blood Transplantation in an Adult Patient with -7/EVI1+ Acute Myeloid Leukemia: a Case Report and Literature Review.
Jiang YZ; Su GP; Dai Y; He HS; Huang LQ; Sun ZM; Huang DP
Ann Clin Lab Sci; 2015; 45(5):598-601. PubMed ID: 26586716
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]